Clin2
NCT05158894Possibly a fitRecruiting

Pregnancy safety registry for migraine medicines Ubrelvy and Qulipta

Migraine

Part of Brain & nervous system clinical trials.

This is an observational study (no treatment is assigned) that tracks side effects and pregnancy outcomes in people taking Ubrelvy or Qulipta for migraine during pregnancy. It may help doctors better understand how these medicines affect mothers and babies.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,884 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are pregnant right now (not someone whose pregnancy already ended).
  • You have a migraine diagnosis from your healthcare provider.
  • You can be in the study if you took Ubrelvy during pregnancy, or took Qulipta during pregnancy, or you are pregnant and did not take these medicines.
  • You must live in the United States or Canada.
  • You can provide contact details and let your healthcare provider share your pregnancy and baby medical info with the registry when asked.
  • You should not have taken other similar migraine medicines (gepants) or CGRP injection medicines close to conception or during pregnancy before joining the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06150781Recruiting
Aimovig pregnancy safety study for migraine

This study tracks the health of pregnant women with migraine who take Aimovig. It helps doctors understand if the medicine is safe to use during pregnancy.

Durham, North Carolina
NCT05046613Recruiting
Pregnancy outcomes after rimegepant use for migraine

This observational study looks at health outcomes for moms, babies, and infants after rimegepant is used during pregnancy for migraine. It may help doctors understand potential risks or reassuring safety information for future pregnancies.

Wilmington, North Carolina
NCT05127954Enrolling by invitation· Phase 3
Long-term migraine tablet study for kids and teens ages 6–17

This study follows kids and teens who already took part in an earlier migraine medication study to check long-term safety and comfort with oral ubrogepant tablets. It may help families understand whether this migraine tablet is safe to keep using over time.

Huntsville, Alabama
NCT06085144Recruiting
Emgality for migraine in breastfeeding women

This trial studies how the migraine medication Emgality (galcanezumab) passes into breastmilk and whether it is safe for nursing babies. It may help new mothers who need migraine treatment while breastfeeding.

San Francisco, California
NCT07310290Recruiting
Study of Ubrogepant for Migraine During the Prodrome Phase

This study looks at how well the migraine medication ubrogepant works when taken during the early signs of a migraine (prodrome). It may help people who already use ubrogepant for their migraines.

Aliso Viejo, California
NCT05125302Recruiting· Phase 3
Ubrogepant for acute migraine relief in kids and teens

This study tests how safe ubrogepant is and whether it helps treat an individual migraine attack in children and teens. It focuses on measuring side effects and whether headaches improve 2 hours after taking the study medicine.

Huntsville, Alabama

Hear when a new Migraine trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.